These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Natural history of cardiovascular disease in patients with diabetes: role of hyperglycemia. Milicevic Z; Raz I; Beattie SD; Campaigne BN; Sarwat S; Gromniak E; Kowalska I; Galic E; Tan M; Hanefeld M Diabetes Care; 2008 Feb; 31 Suppl 2():S155-60. PubMed ID: 18227478 [TBL] [Abstract][Full Text] [Related]
30. [Training after percutaneous coronary intervention- an undervalued treatment option?]. Munk PS; Larsen AI Tidsskr Nor Laegeforen; 2007 May; 127(10):1365-7. PubMed ID: 17519991 [TBL] [Abstract][Full Text] [Related]
31. Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries. Motovska Z; Kala P Clin Ther; 2008; 30 Pt 2():2191-202. PubMed ID: 19281914 [TBL] [Abstract][Full Text] [Related]
32. Performance measures have a major effect on cardiovascular outcomes: a review. Mehta RH; Peterson ED; Califf RM Am J Med; 2007 May; 120(5):398-402. PubMed ID: 17466646 [TBL] [Abstract][Full Text] [Related]
33. Plasma levels of soluble receptor for advanced glycation end products are associated with endothelial function and predict cardiovascular events in nondiabetic patients. Chiang KH; Huang PH; Huang SS; Wu TC; Chen JW; Lin SJ Coron Artery Dis; 2009 Jun; 20(4):267-73. PubMed ID: 19440065 [TBL] [Abstract][Full Text] [Related]
34. Heart rate as a treatable cardiovascular risk factor. Tardif JC Br Med Bull; 2009; 90():71-84. PubMed ID: 19474056 [TBL] [Abstract][Full Text] [Related]
35. Cardiovascular protection paradigms: is change on the horizon? Papademetriou V Rev Cardiovasc Med; 2007; 8(4):200-13. PubMed ID: 18192943 [TBL] [Abstract][Full Text] [Related]
36. More knocks to the oxidation hypothesis for vascular disease? Mullan A; Sattar N Clin Sci (Lond); 2009 Jan; 116(1):41-3. PubMed ID: 18844607 [TBL] [Abstract][Full Text] [Related]
38. Significance of a multiple biomarkers strategy including endothelial dysfunction to improve risk stratification for cardiovascular events in patients at high risk for coronary heart disease. Nozaki T; Sugiyama S; Koga H; Sugamura K; Ohba K; Matsuzawa Y; Sumida H; Matsui K; Jinnouchi H; Ogawa H J Am Coll Cardiol; 2009 Aug; 54(7):601-8. PubMed ID: 19660689 [TBL] [Abstract][Full Text] [Related]
39. Mechanisms of ET-1-induced endothelial dysfunction. Iglarz M; Clozel M J Cardiovasc Pharmacol; 2007 Dec; 50(6):621-8. PubMed ID: 18091577 [TBL] [Abstract][Full Text] [Related]
40. Endothelial dysfunction in obesity: etiological role in atherosclerosis. Meyers MR; Gokce N Curr Opin Endocrinol Diabetes Obes; 2007 Oct; 14(5):365-9. PubMed ID: 17940464 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]